The global genomics assays market is predicted to show steady growth through 2025. Rising incidences of chronic diseases and lifestyle disorders such as cancer, diabetes, cardiovascular and neurological disorders require solutions that can eradicate the issue at a genetic or molecular level. This has fueled the rise of genomics and therefore, the genomic assays market is growing. Furthermore, the outbreak of COVID-19 has led to the increased adoption of next-generation sequencing (NGS) and PCR technologies among researchers. Several companies have introduced consumables and modified their genomic platforms in order to facilitate the use of NGS and PCR technologies for COVID-19 research. However, in order to effectively capture value from the growing market demand, companies in the genomic assays market must overcome some of the below mentioned key challenges.
Infiniti Research has 15+ years of experience working in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. Request a complimentary proposal to know more about how you can overcome key business challenges by leveraging our custom market intelligence.
Storage and analysis of large datasets for genomics
As the adoption of genomic technologies rises in the medical world, the number of patients who are undergoing genetic tests or treatments is also consequently growing. Additionally, it is anticipated that a greater number of healthy individuals will seek genomic technologies for predicting personal health risks. With the increasing usage of genomics for healthcare purposes, huge amounts of data are being generated. The storage, distribution, and analysis of these large datasets require massive and high-end technological solutions. Providing such solutions is a challenge for many countries. Additionally, a large amount of data leads to concerns about data privacy and data security.
Acquiring high-quality single-cell sequencing data
With the recent boom in the field of microfluidics and combinatorial indexing strategies, and reducing sequencing costs, single-cell sequencing technology has been developing at a fast pace. Thousands and millions of cells are analyzed in a single experiment, thereby amounting to a data revolution in genomic sequencing. The general purpose of single-cell (sc) DNA sequencing is to track somatic evolution at the cellular level. Receiving high-quality data from single-cell (sc) sequencing is a challenge as it involves data at the cellular level. This is also another major reason for the shifting preference to multiplex sequencing.
Cost of building a platform
Genomic platforms need extensive IT capabilities and should be capable of synchronizing with the available equipment in a laboratory. Furthermore, it should be capable of addressing and analyzing different types of sequencing technologies. There is multiple software (ones that are capable of being installed or plugged in an existing platform) that address specific needs. For an end-user who is already subscribed to a platform, opting for plug-and-play software is economically viable. Therefore, this poses a challenge for companies that plan on building a new platform entirely that is extensive enough to cater to all the needs of users in the genomic assays market.
Need for uniform standard operating procedures for platforms
Operations on genomics platform differ from one to another depending on their manufacturer. With such variance in functionalities between platforms and software, it is difficult for a user to migrate from one platform to another if such a need arises. Also, information sharing between the platform becomes a challenge in such cases.
For more insights into the market trends, key drivers, and challenges in the global genomic assays market, request more information.